

# Roberto Marchioli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1050828/publications.pdf>

Version: 2024-02-01

117  
papers

14,393  
citations

71004

43  
h-index

26792

111  
g-index

121  
all docs

121  
docs citations

121  
times ranked

15367  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins â€” Confirmation from PCSK9 Inhibitor Studies. <i>American Journal of Medicine</i> , 2020, 133, 95-99.e6.	0.6	14
2	Prospective Evaluation of Clinico-Pathological Predictors of Postoperative Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008382.	2.1	6
3	Cancer in chronic heart failure patients in the GISSIâ€”HF trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13273.	1.7	8
4	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	6.3	512
5	IGENDA protocol: gender differences in awareness, knowledge and perception of cardiovascular risk: An Italian multicenter study. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 278-283.	0.6	5
6	Modes of death and prognostic outliers in chronic heart failure. <i>American Heart Journal</i> , 2019, 208, 100-109.	1.2	7
7	Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza) Tj ETQq1 1 0.784314 rgBT /Overload 205-215.	1.5	30
8	Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. <i>JAMA Cardiology</i> , 2018, 3, 225.	3.0	526
9	Fish Oil Supplementation Does Not Affect Cognitive Outcomes in Cardiac Surgery Patients in the Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation (OPERA) Trial. <i>Journal of Nutrition</i> , 2018, 148, 472-479.	1.3	5
10	Factors associated with postoperative atrial fibrillation and other adverse events after cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 242-251.e10.	0.4	34
11	Fish Oil and Perioperative Bleeding. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004584.	0.9	36
12	Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 44, 16-23.	1.1	16
13	Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. <i>Cardiology</i> , 2017, 136, 128-137.	0.6	46
14	Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardicoâ€”Heart Failure trial. <i>Nutrition Research</i> , 2016, 36, 989-994.	1.3	30
15	Global cardiovascular risk evaluation. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 581-586.	0.6	3
16	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. <i>Data in Brief</i> , 2016, 7, 1541-1550.	0.5	1
17	A low plasma 1,25(OH) 2 vitamin D/PTH (1â€”84) ratio predicts worsening of renal function in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 220-225.	0.8	12
18	Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT. <i>Atherosclerosis</i> , 2016, 248, 216-218.	0.4	18

#	ARTICLE	IF	CITATIONS
19	Oxidative Stress Biomarkers and Incidence of Postoperative Atrial Fibrillation in the Omega-3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	43
20	Circulating cardiac biomarkers and postoperative atrial fibrillation in the OPERA trial. <i>European Journal of Clinical Investigation</i> , 2015, 45, 170-178.	1.7	23
21	Prognostic impact of metabolic syndrome in patients with chronic heart failure: Data from GISSI-HF trial. <i>International Journal of Cardiology</i> , 2015, 178, 85-90.	0.8	18
22	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015, 36, 1536-1546.	1.0	126
23	Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2543-2551.	0.6	29
24	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015, 385, 351-361.	6.3	562
25	Aspirin Therapy in Primary Cardiovascular Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 319-327.	1.2	150
26	Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials. <i>International Journal of Cardiology</i> , 2014, 172, 403-410.	0.8	36
27	Abstract 12364: Circulating Cardiac and Inflammatory Biomarkers to Predict Post-Operative Atrial Fibrillation in the OPERA Trial. <i>Circulation</i> , 2014, 130, .	1.6	0
28	Wine consumption and risk of cardiovascular events after myocardial infarction: Results from the GISSI-Prevenzione trial. <i>International Journal of Cardiology</i> , 2013, 163, 282-287.	0.8	42
29	Predictors of Mortality in 6975 Patients With Chronic Heart Failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2013, 6, 31-39.	1.6	101
30	n-3 PUFAs in cardiovascular disease. <i>International Journal of Cardiology</i> , 2013, 170, S33-S38.	0.8	21
31	n-3 PUFAs and heart failure. <i>International Journal of Cardiology</i> , 2013, 170, S28-S32.	0.8	9
32	n-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1289-1295.	2.9	33
33	Uric acid: A cardiovascular risk factor in patients with recent myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 167, 262-269.	0.8	41
34	n-3PUFA and Holter-derived autonomic variables in patients with heart failure: Data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy. <i>Heart Rhythm</i> , 2013, 10, 226-232.	0.3	23
35	Fish Oil and Post-Operative Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2194-2196.	1.2	52
36	n-3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors. <i>New England Journal of Medicine</i> , 2013, 368, 1800-1808.	13.9	464

#	ARTICLE	IF	CITATIONS
37	Plasma Phospholipid Omega-3 Fatty Acids and Incidence of Postoperative Atrial Fibrillation in the OPERA Trial. <i>Journal of the American Heart Association</i> , 2013, 2, e000397.	1.6	24
38	Fish Oil vs Olive Oil for Postoperative Atrial Fibrillation—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 871.	3.8	2
39	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. <i>New England Journal of Medicine</i> , 2013, 368, 22-33.	13.9	664
40	Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. <i>Haematologica</i> , 2013, 98, 1421-1423.	1.7	11
41	A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results. <i>Blood</i> , 2013, 122, 1583-1583.	0.6	4
42	Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte®) In Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013, 122, 3901-3901.	0.6	0
43	Why Do We Still Need Large Scale Clinical Trial: The Case of n-3 PUFA. <i>Frontiers in Physiology</i> , 2012, 3, 202.	1.3	2
44	Fish Oil and Postoperative Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2001.	3.8	201
45	Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2012, 14, 1410-1419.	2.9	64
46	Polycythemia vera: gender-related phenotypic differences. <i>Internal and Emergency Medicine</i> , 2012, 7, 509-515.	1.0	19
47	How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort. <i>Blood</i> , 2012, 120, 1748-1748.	0.6	1
48	A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial). <i>Blood</i> , 2012, 120, 4-4.	0.6	3
49	Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses — First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial. <i>Blood</i> , 2012, 120, 550-550.	0.6	8
50	Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL). <i>Blood</i> , 2012, 120, 746-746.	0.6	3
51	In Vivo T Cell Depletion with Antithymocyte Globulin or Alemtuzumab for Unrelated Donor Stem Cell Transplantation with Reduced Intensity Conditioning: Results of a Multicenter Randomized Phase II Clinical Trial (The Global Study) From the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , 2012, 120, 221-221.	0.6	0
52	The n-3 fatty acids for Prevention of Post-Operative Atrial Fibrillation trial—rationale and design. <i>American Heart Journal</i> , 2011, 162, 56-63.e3.	1.2	31
53	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. <i>Haematologica</i> , 2011, 96, 315-318.	1.7	160
54	Corrigendum to “Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial” [Eur J Heart Fail 2010;12:1345-1353]. <i>European Journal of Heart Failure</i> , 2011, 13, 1042-1042.	2.9	1

#	ARTICLE	IF	CITATIONS
55	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. <i>Blood</i> , 2011, 118, 1750-1750.	0.6	2
56	Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. <i>American Journal of Hematology</i> , 2010, 85, 616-619.	2.0	18
57	Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease. <i>Journal of Multidisciplinary Healthcare</i> , 2010, 3, 79.	1.1	7
58	Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 65-72.	1.6	101
59	Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2010, 12, 1345-1353.	2.9	75
60	The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. <i>European Journal of Heart Failure</i> , 2010, 12, 338-347.	2.9	129
61	Cholesterol-Lowering Interventions and Stroke. <i>Journal of the American College of Cardiology</i> , 2010, 55, 198-211.	1.2	88
62	Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed. <i>American Heart Journal</i> , 2010, 159, 245-257.	1.2	106
63	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. <i>Lancet, The</i> , 2010, 375, 735-742.	6.3	2,064
64	A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results. <i>Blood</i> , 2010, 116, 314-314.	0.6	7
65	Pediatric-Type Therapy Including Lineage-Targeted Methotrexate to Improve Early Minimal Residual Disease Response and Survival In Adult Acute Lymphoblastic Leukemia (ALL): Interim Analysis of Northern Italy Leukemia Group Study 10/07. <i>Blood</i> , 2010, 116, 2131-2131.	0.6	1
66	Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. <i>European Heart Journal</i> , 2009, 30, 2327-2336.	1.0	98
67	Omega-3 fatty acids and heart failure. <i>Current Atherosclerosis Reports</i> , 2009, 11, 440-447.	2.0	22
68	Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 735-748.	0.6	37
69	A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).. <i>Blood</i> , 2009, 114, 754-754.	0.6	19
70	High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.. <i>Blood</i> , 2009, 114, 1220-1220.	0.6	0
71	Correlation of Novel Molecular Markers in Patients with Myeloproliferative Neoplasms.. <i>Blood</i> , 2009, 114, 4968-4968.	0.6	2
72	Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 372, 1231-1239.	6.3	954

#	ARTICLE	IF	CITATIONS
73	Omega-3 Fatty Acids for Cardioprotection. Mayo Clinic Proceedings, 2008, 83, 324-332.	1.4	218
74	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 2008, 93, 372-380.	1.7	316
75	Are All Fish Equally Close to the Heart?â€“Reply. Mayo Clinic Proceedings, 2008, 83, 724-725.	1.4	0
76	Coffee Consumption and Risk of Cardiovascular Events After Acute Myocardial Infarction. Circulation, 2007, 116, 2944-2951.	1.6	55
77	Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood, 2007, 109, 2446-2452.	0.6	356
78	Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood, 2007, 109, 2310-2313.	0.6	295
79	Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. European Heart Journal, 2007, 28, 1977-1983.	1.0	31
80	A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. American Heart Journal, 2007, 153, 1037-1047.	1.2	200
81	Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet, The, 2007, 370, 667-675.	6.3	153
82	The haematocrit and platelet target in polycythemia vera. British Journal of Haematology, 2007, 136, 249-259.	1.2	162
83	Meta-Analysis of Effect of Statin Treatment on Risk of Sudden Death. American Journal of Cardiology, 2007, 100, 1644-1650.	0.7	41
84	A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis.. Blood, 2007, 110, 3540-3540.	0.6	39
85	A GILL Prospective Randomized Multicenter Phase III Study of High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Transplantation (ASCT) of Peripheral Blood Stem Cells Versus CHOP and Rituximab Delivered Every 14 Days (R-CHOP-14) in High-Risk Patients with Diffuse Large B-Cell Lymphomas (DLBCL): Interim Analysis on Feasibility and Toxicity (Protocol R-HDS 0305).. Blood, 2007, 110, 1888-1888.	0.6	1
86	Current Treatment Approaches of Polycythemia Vera. Clinical Leukemia, 2006, 1, 41-45.	0.2	1
87	Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. Journal of Cardiovascular Medicine, 2006, 7, 347-350.	0.6	96
88	Analysis of the Benefits of a Mediterranean Diet in the GISSI-Prevenzione Study: A Case Study in Imputation of Missing Values from Repeated Measurements. European Journal of Epidemiology, 2006, 21, 15-24.	2.5	12
89	Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level. Vascular Health and Risk Management, 2006, 2, 507-514.	1.0	18
90	Leukocytosis as an Independent Risk Factor for Thrombosis in Polycythemia Vera.. Blood, 2006, 108, 115-115.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Clinical Significance of JAK2V617F Homozygosity in the Chronic Myeloproliferative Disorders. A Study on 1306 Patients.. Blood, 2006, 108, 664-664.	0.6	3
92	Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood, 2005, 105, 2664-2670.	0.6	389
93	Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. European Journal of Heart Failure, 2005, 7, 904-909.	2.9	101
94	Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera. Journal of Clinical Oncology, 2005, 23, 2224-2232.	0.8	631
95	Clinical Trials in Myeloproliferative Disorders: Looking Forward. Seminars in Hematology, 2005, 42, 259-265.	1.8	9
96	Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction. Journal of the American College of Cardiology, 2005, 46, 277-283.	1.2	147
97	Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels. Haematologica, 2005, 90, 851-3.	1.7	8
98	Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. New England Journal of Medicine, 2004, 350, 114-124.	13.9	911
99	Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure, 2004, 6, 635-641.	2.9	214
100	Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids. European Journal of Clinical Pharmacology, 2004, 60, 183-190.	0.8	68
101	Prognosis of Venous Occlusive Disease after Stem Cell Transplantation in the DF-VOD Trial. On behalf of the DF-VOD Investigators:.. Blood, 2004, 104, 1137-1137.	0.6	4
102	Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction. Circulation, 2002, 105, 1897-1903.	1.6	1,213
103	Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects. Thrombosis and Haemostasis, 2002, 87, 58-67.	1.8	5
104	Cholesterol Reduction and Stroke Occurrence: An Overview of Randomized Clinical Trials. Cerebrovascular Diseases, 2000, 10, 85-92.	0.8	97
105	Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases. Current Cardiology Reports, 2000, 2, 293-299.	1.3	51
106	Cardiovascular risk changes after lipid lowering medications: are they predictable?. Atherosclerosis, 2000, 152, 1-8.	0.4	14
107	Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1368-1377.	1.1	287
108	GISSI-Prevenzione trial. Lancet, The, 1999, 354, 1556-1557.	6.3	26

#	ARTICLE	IF	CITATIONS
109	Diet and gallstones in italy: The cross-sectional MICOL results. Hepatology, 1998, 27, 1492-1498.	3.6	70
110	The yield of meta-analysis. Lancet, The, 1998, 351, 915-916.	6.3	1
111	Hypertension Optimal Treatment (HOT) trial. Lancet, The, 1998, 352, 571-572.	6.3	8
112	European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): A Randomized Trial. Seminars in Thrombosis and Hemostasis, 1997, 23, 473-478.	1.5	64
113	Chronic infections and coronary heart disease. Lancet, The, 1997, 350, 1028-1029.	6.3	3
114	BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. British Journal of Haematology, 1997, 99, 379-385.	1.2	24
115	Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma. British Journal of Haematology, 1997, 96, 620-626.	1.2	8
116	A Positive Relation between High Hemoglobin Values and the Risk of Ischemic Stroke. European Neurology, 1996, 36, 85-88.	0.6	10
117	Family history and socioeconomic factors as predictors of myocardial infarction, unstable angina and stroke in an Italian population. European Journal of Epidemiology, 1996, 12, 177-185.	2.5	22